Accelerated Predictive Stability Testing: Accelerating Registration Phase and Application of Reduced Designs for Shelf-Life Determination of Parenteral Drug Product
Pharmaceutics · 25.01.2025 · 17 (2) · 160
DOI: 10.3390/pharmaceutics17020160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 25.01.2025. Verfasst von Lara Pavčnik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sandoz Development Center Slovenia, Lek Pharmaceuticals d.d., Verovškova 57, SI-1526 Ljubljana, Slovenia. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
This article explores the applicability of the accelerated stability assessment program (ASAP) in stability studies for parenteral medications. Conventional stability testing requires extensive evaluation over the entire shelf life of a product, which can be very time-consuming. In contrast, ASAP provides an efficient approach to support drug product development and expedite regulatory procedures.
Methods
The study involved subjecting the medication to different stress and long-term stability conditions and monitoring the formation of degradation products. A systematic methodology was employed to evaluate the stress stability data of the parenteral medication using various designs (full and reduced). ASAP models were then developed from these data and assessed using the statistical parameters R2 (coefficient of determination) and Q2 (predictive relevance). To validate the accuracy of the models, the predicted levels of degradation products from each of the 13 models were compared with the actual long-term stability results using the relative difference parameter.
Results
The results confirmed the suitability of the evaluated full model and 11 reduced models for predicting degradation products, except for the two-temperature model, demonstrating the effectiveness of ASAP in stability studies and providing reliable predictions. However, the three-temperature model was identified as the most appropriate model for the parenteral medication under investigation. The statistical analyses showed high R2 and Q2 values, indicating robust model performance and predictive accuracy. Consequently, we applied the selected model on various formulations, demonstrating the suitability of the model and impurity levels below the ICH specification limit.
Conclusions
This research enhances understanding of how ASAP designs can be applied to stability studies for parenteral medications and demonstrates the significance of the application of ASAP during drug product development to expedite the initiation of procedures and implement post-approval variations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sandoz Development Center Slovenia, Lek Pharmaceuticals d.d., Verovškova 57, SI-1526 Ljubljana, Slovenia.
- Department of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
ORCID-Profile: Robert Roškar
Zitieren
APA
Pavčnik, L., Prunk, M., Trdan Lušin, T., & Roškar, R. (2025). Accelerated Predictive Stability Testing: Accelerating Registration Phase and Application of Reduced Designs for Shelf-Life Determination of Parenteral Drug Product. Pharmaceutics, 17(2), 160. https://doi.org/10.3390/pharmaceutics17020160
Vancouver
Pavčnik L, Prunk M, Trdan Lušin T, Roškar R. Accelerated Predictive Stability Testing: Accelerating Registration Phase and Application of Reduced Designs for Shelf-Life Determination of Parenteral Drug Product. Pharmaceutics. 2025;17(2):160. doi:10.3390/pharmaceutics17020160
BibTeX
@article{Pavnik2025,
author = {Pavčnik, Lara and Prunk, Mateja and Trdan Lušin, Tina and Roškar, Robert},
title = {Accelerated Predictive Stability Testing: Accelerating Registration Phase and Application of Reduced Designs for Shelf-Life Determination of Parenteral Drug Product},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {2},
pages = {160},
doi = {10.3390/pharmaceutics17020160}
}
EUVIMED